ArticlePharmaceuticals (Basel, Switzerland)2025

First-in-Human Phase I Clinical Trial of SLC-391, a Novel and Selective AXL Inhibitor, in Patients with Advanced Solid Tumours.

Zaihui Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.